股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 星悅康旅股份有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03662 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/ ...

Core Viewpoint - Xingyue Kanglv (03662) announced a leasing agreement for a property in Panyu, Guangzhou, which will be used for legitimate commercial activities over a 10-year period from February 1, 2026, to January 31, 2036 [1] Group 1 - The company’s wholly-owned subsidiary, Guangzhou Panyu Yuexi, has entered into a lease agreement with Hengqin Shenhe Asset Operation, an independent third party [1] - The leased property is located at Panyu Aoyuan Plaza [1] - The lease term is set for 10 years, starting from February 1, 2026, and ending on January 31, 2036 [1]

智通财经APP讯，星悦康旅(03662)发布公告，于2026年1月14日，公司全资附属公司广州番禺悦禧(作为 承租方)与出租方横琴深合资产运营(独立第三方)订立租赁合同，据此，出租方同意根据租赁合同，将位 于番禺奥园广场的租赁物业出租予广州番禺悦禧，用于合法商业经营活动，租期为10年，自2026年2月1 日起至2036年1月31日止。 ...

格隆汇1月23日丨星悦康旅(03662.HK)公告，于2026年1月14日，公司全资附属公司广州番禺悦禧(作为 承租方)与出租方横琴深合资产运营(独立第三方)订立租赁合同，据此，出租方同意根据租赁合同，将位 于番禺奥园广场的租赁物业出租予广州番禺悦禧，用于合法商业经营活动，租期为10年，自2026年2月1 日起至2036年1月31日止。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 星 悅 康旅股份有限公司 Starjoy Wellness and Travel Company Limited （於開曼群島註冊成立的有限責任公司） （股份代號：3662） 須予披露交易 訂立租賃合同 董 事 會 宣 佈，於 二 零 二 六 年 一 月 十 四 日，本 公 司 全 資 附 屬 公 司 廣 州 番 禺 悅 禧 （作 為 承 租 方）與 出 租 方（獨 立 第 三 方）訂 立 租 賃 合 同，據 此，出 租 方 同 意 根 據 租 賃 合 同，將 位 於 番 禺 奧 園 廣 場 的 租 賃 物 業 出 租 予 廣 州 番 禺 悅 禧，用 於 合 法 商 業 經 營 活 動，租 期 為10年，自 二 零 二 六 年 二 月 一 日 起 至 二 零 三 六 年 一 月 三 十 一 日 止。 根據國際財務報告準則第16號「租 賃」，本 公 ...

Core Viewpoint - The Hong Kong Stock Exchange has criticized and taken disciplinary action against Xingyue Kanglv (formerly known as Aoyuan Health) and China Aoyuan, along with 15 directors from both companies, for violating listing rules through improper financial assistance transactions that occurred around 2021 [3][4]. Group 1: Disciplinary Actions - Xingyue Kanglv and its subsidiary provided financial assistance to China Aoyuan and its subsidiaries, violating listing rules [3]. - Key figures involved include Guo Zining, who was identified as the main orchestrator of the fund transfers, and Chen Zhibin, who facilitated these transactions [4]. - A total of 33 billion RMB was transferred through 147 transactions from January 1, 2021, to March 31, 2022, primarily as short-term loans [3][5]. Group 2: Internal Investigations and Findings - Following the revelation of the fund transfers, both companies suspended trading on April 1, 2022, and established independent investigation committees [5]. - The investigations uncovered significant deficiencies in internal controls, including the management of conflicts of interest and approval processes [5]. - Despite the financial assistance, China Aoyuan did not recover from its debt issues, and Xingyue Kanglv faced a decline in revenue by approximately 13% and a core net profit drop of over 41% in the first half of 2025 [5].

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has criticized and condemned a past violation involving financial "blood transfusions" between Xingyue Kanglv (formerly known as Aoyuan Health) and China Aoyuan, along with disciplinary actions against 15 directors of both companies [1][2]. Group 1: Disciplinary Actions - Xingyue Kanglv and its subsidiary, referred to as "Xingyue Group," provided financial assistance to China Aoyuan and its subsidiaries, violating the Listing Rules [1]. - The disciplinary actions include reprimands for Xingyue Kanglv and its former chairman, CEO, and non-executive director, as well as for China Aoyuan's former vice chairman and CEO [1][2]. - A total of 33 billion RMB was transferred from Xingyue Group to Aoyuan Group through 147 transactions between January 1, 2021, and March 31, 2022, primarily as short-term loans [1]. Group 2: Key Individuals Involved - Guo Zining is identified as the main architect behind the fund transfers, prioritizing the interests of China Aoyuan over those of Xingyue Kanglv, which led to significant liquidity pressure on Xingyue Kanglv [2]. - Chen Zhibin, the former CFO of China Aoyuan, facilitated the fund transfers and approved 118 out of the 147 transactions, failing to manage conflicts of interest [2]. - Zheng Wei, a former executive director of Xingyue Kanglv, approved 122 transactions without exercising independent judgment or seeking board approval [2]. Group 3: Consequences and Investigations - Following the revelation of the fund transfers, both companies were suspended from trading on April 1, 2022, and established independent committees to investigate the matter [3]. - The investigation revealed significant deficiencies in internal controls regarding related party transactions and conflict management [3]. - Despite attempts to alleviate China Aoyuan's debt issues, the financial strain severely impacted Xingyue Kanglv, which reported a 13% decline in revenue and over 41% drop in core net profit in its mid-2025 report [3].

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has taken disciplinary action against Xingyue Kanglv (formerly Aoyuan Health Life), China Aoyuan, and 15 of their directors due to improper fund transfers amounting to approximately 3.3 billion yuan, which violated listing rules [1][3]. Group 1: Disciplinary Actions and Violations - The disciplinary action involves the transfer of approximately 3.3 billion yuan from Xingyue Kanglv to China Aoyuan through 147 transactions between January 1, 2021, and March 31, 2022, with 118 of these transactions lacking board approval [3]. - Key figures involved include Guo Zining, the former chairman and CEO of Xingyue Kanglv, identified as the main orchestrator of the fund transfer, along with Chen Zhibin and Zheng Wei, who approved most transactions despite knowing the liquidity crisis faced by China Aoyuan [3][4]. - The HKEX has issued "director unsuitability statements and reprimands" against Guo Zining, Chen Zhibin, and Zheng Wei, with the latter two also being reprimanded for harming investor interests [1][8]. Group 2: Background and Consequences - The fund transfer was initiated during a period of financial distress for China Aoyuan, which was facing a liquidity crisis due to the "three red lines" regulatory policy [3]. - An anonymous report in April 2022 accused Xingyue Kanglv of various financial misreporting, including underreporting bank loan balances and failing to disclose financial guarantees to the parent company [4]. - The financial mismanagement has led to significant operational challenges for Xingyue Kanglv, with reported declines in managed area and net profit, including a 42.2% drop in net profit for 2024 [8]. Group 3: Broader Industry Context - The situation with Xingyue Kanglv reflects a broader trend in the industry, where several listed property companies have faced similar issues of fund misappropriation by parent companies, including New城悦服务 and 恒大物业 [8][9]. - The HKEX has mandated compliance training for the involved directors, highlighting the regulatory scrutiny on corporate governance within the real estate sector [8].

Core Viewpoint - The Hong Kong Stock Exchange announced disciplinary actions against Xingyue Kanglv Co., Ltd. (formerly known as Aoyuan Health Life Group Co., Ltd.) and 15 directors of the company for providing financial assistance of 3.3 billion RMB to its then-listed controlling shareholder, China Aoyuan, without complying with the Listing Rules [1] Group 1 - The financial assistance was provided through 147 transactions between January 1, 2021, and March 31, 2022 [1] - China Aoyuan faced severe liquidity issues during the specified period, prompting the financial support from Xingyue Kanglv [1] - The violation of the Listing Rules was attributed to the failure of the relevant directors to fulfill their duties [1]

Core Viewpoint - The Hong Kong Stock Exchange has condemned Star Health Travel Holdings Limited and several of its directors for failing to comply with listing rules, particularly regarding financial assistance provided to its parent company, China Aoyuan Group, amidst liquidity issues [1][2][3] Group 1: Disciplinary Actions - The Hong Kong Stock Exchange issued a statement condemning multiple directors from Star Health Travel and China Aoyuan for their roles in the violations, including Mr. Guo Zining, Mr. Chen Zhibin, and Mr. Zheng Wei [1] - Specific directors have been mandated to complete training hours, with Mr. Guo Zining and others required to complete 17 hours, while others, including Mr. Ruan Yongxi and Dr. Li Zijun, must complete 26 hours [2] Group 2: Financial Assistance Violations - Star Health Travel provided 3.3 billion RMB in financial assistance to China Aoyuan without adhering to the listing rules, which is a significant breach [2] - Between January 1, 2021, and March 31, 2022, Star Health Travel engaged in 147 transactions to provide this financial support, despite being aware of China Aoyuan's liquidity issues [2] Group 3: Director Responsibilities - The violations were attributed to the failure of the directors to fulfill their responsibilities, particularly in seeking board approval and ensuring compliance with listing rules [3] - Mr. Guo Zining and Mr. Chen Zhibin were noted as the main planners of the financial assistance, prioritizing China Aoyuan's interests over those of Star Health Travel [3] - Other directors, while not directly approving the transactions, failed to act in the best interests of Star Health Travel, indicating a lack of adequate internal controls [3]